hUrology Clinics of North Texas, Dallas, Texas; American Urological Association. iUniversity of Wisconsin, Madison, Wisconsin. jUPMC, Pittsburgh, Pennsylvania; American Urological Association. kSutter Medical Group, Sacramento, California; Commission on Radiation Oncology. lOttawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada. mEmory University, Atlanta, Georgia; Commission on Nuclear Medicine and Molecular Imaging. nThe University of Texas MD Anderson Cancer Center, Houston, Texas. oSpecialty Chair, University of Alabama at Birmingham, Birmingham, Alabama. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through representation of such organizations on expert panels. Participation on the expert panel does not necessarily imply endorsement of the final document by individual contributors or their respective organization. Reprint requests to: publications@acr.org Post-Treatment Follow-up of Prostate Cancer much higher. MRI can identify isolated local recurrences very early, with PSA levels <1 ng/mL [10]. Nodal staging is still a significant diagnostic challenge, because CT and MRI have limited accuracy because of the dependence on size criteria, which is a poor predictor of prostate cancer nodal metastasis. There are currently 4 FDA-approved prostate-specific PET agents for prostate cancer recurrence: 1) carbon-11 choline (C-11 choline), 2) F-18 fluciclovine (also known as anti-1-amino-3-[18-F]-fluorocyclobutane-1-carboxylic acid, [FACBC]), 3) Ga-68-prostate-specific membrane antigen (PSMA)-11, and 4) DCFPyL (2-(3-{1-carboxy-5-[(6-[(18)F]fluoro- pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid). There is a great deal of data for all 4 radiotracers on the performance showing their usefulness for nodal and bone lesion identification.
Post Treatment Follow up of Prostate Cancer. hUrology Clinics of North Texas, Dallas, Texas; American Urological Association. iUniversity of Wisconsin, Madison, Wisconsin. jUPMC, Pittsburgh, Pennsylvania; American Urological Association. kSutter Medical Group, Sacramento, California; Commission on Radiation Oncology. lOttawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada. mEmory University, Atlanta, Georgia; Commission on Nuclear Medicine and Molecular Imaging. nThe University of Texas MD Anderson Cancer Center, Houston, Texas. oSpecialty Chair, University of Alabama at Birmingham, Birmingham, Alabama. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through representation of such organizations on expert panels. Participation on the expert panel does not necessarily imply endorsement of the final document by individual contributors or their respective organization. Reprint requests to: publications@acr.org Post-Treatment Follow-up of Prostate Cancer much higher. MRI can identify isolated local recurrences very early, with PSA levels <1 ng/mL [10]. Nodal staging is still a significant diagnostic challenge, because CT and MRI have limited accuracy because of the dependence on size criteria, which is a poor predictor of prostate cancer nodal metastasis. There are currently 4 FDA-approved prostate-specific PET agents for prostate cancer recurrence: 1) carbon-11 choline (C-11 choline), 2) F-18 fluciclovine (also known as anti-1-amino-3-[18-F]-fluorocyclobutane-1-carboxylic acid, [FACBC]), 3) Ga-68-prostate-specific membrane antigen (PSMA)-11, and 4) DCFPyL (2-(3-{1-carboxy-5-[(6-[(18)F]fluoro- pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid). There is a great deal of data for all 4 radiotracers on the performance showing their usefulness for nodal and bone lesion identification.